<img height="1" width="1" style="display:none;" alt="" src="https://px.ads.linkedin.com/collect/?pid=2849132&amp;fmt=gif">
Healthcare-Institutions_Icon

BioTech and Pharma

Pharmaceutical and BioTech Network Segmentation with Manufacturing System Microsegmentation

Pharmaceutical and biotech manufacturing, have complex cyber-physical environments where drug discovery, clinical trials, and production systems interconnect. Elisity's identity-based microsegmentation empowers pharmaceutical enterprises to secure their manufacturing operations, protect intellectual property, and maintain regulatory compliance while achieving FDA cybersecurity guidelines and IEC 62443 standards without disrupting critical production processes.

Challenges

Pharmaceutical and biotech organizations with multiple manufacturing sites, R&D facilities, and global supply chains face unprecedented security challenges as operational technology (OT) systems connect to enterprise networks. Traditional network segmentation approaches cannot protect these highly regulated environments without risking production downtime or compromising Good Manufacturing Practices (GMP).

Healthcare_institution_employees_at_work
Small_Logo
GSK-Logo-Small

Customer Spotlight

“Elisity’s deployment at GSK is nothing short of revolutionary, making every other solution pale in comparison.”

— Michael Elmore, CISO, GSK

Home_Eyebrow

Network Segmentation Without Compromise

Transform network security with identity-based microsegmentation that enables Zero Trust in weeks, not years.

The Numbers

Main Line Health deploys Elisity microsegmentation enterprise-wide across their Cisco infrastructure with Armis integration, providing comprehensive protection at every facility with network presence.

270+

Actively Enforced Policies

302,000

Devices Protected by Microsegmentation Policies

110

Gloabl Sites - Manufacturing, Labs, Orrices

3

As GSK rides the wave of global expansion, it successfully initiates three new Elisity-powered sites every week.

Challenge

Expanded Manufacturing Attack Surface

The convergence of IT and OT in pharmaceutical manufacturing has created new attack vectors that cybercriminals exploit to steal intellectual property, disrupt production, or compromise drug safety. With thousands of connected devices spanning multiple sites globally, pharmaceutical companies struggle to maintain visibility and control while meeting stringent FDA requirements.​

Down_arrow
challenge-solution_icon

Elisity Solution

Comprehensive Manufacturing Visibility

Elisity IdentityGraph™ transforms your switches into intelligent sensors that automatically discover and classify all connected assets—including bioreactors, SCADA systems, laboratory equipment, and building management systems—providing complete visibility across your entire pharmaceutical manufacturing environment without disrupting validated processes.

Challenge

Legacy OT System Vulnerabilities

Manufacturing equipment and process control systems often run proprietary software with 10-15 year lifecycles, making them impossible to patch without lengthy revalidation. These systems represent critical infrastructure for drug production but remain unprotected by conventional security tools.

Down_arrow
challenge-solution_icon

Elisity Solution

FDA-Compliant Segmentation

Implement the zone and conduit architecture required by FDA's OT cybersecurity guidance and IEC 62443 standards through identity-based policy groups that segment your manufacturing environment without complex VLAN configurations or network changes. Our solution ensures compliance with 21 CFR Part 11 and cGMP requirements.

Challenge

Regulatory Compliance Complexity

Meeting FDA cybersecurity guidelines, IEC 62443 requirements, and maintaining GMP compliance while implementing security controls creates operational challenges. Traditional approaches require extensive validation documentation and risk disrupting qualified systems.

Down_arrow
challenge-solution_icon

Elisity Solution

Zero-Disruption Deployment

Deploy pharmaceutical microsegmentation using your existing network infrastructure without new hardware, agents on validated systems, or production downtime—maintaining continuous manufacturing operations critical to drug supply chains.

Frame 427319008

Supply Chain and IP Protection

Pharmaceutical companies cannot tolerate security implementations that risk intellectual property theft or supply chain disruption, creating resistance to implementing proper controls while maintaining global operations across contract manufacturers and research partners.

Down_arrow
challenge-solution_icon

Elisity Solution

Phased Security Implementation

Roll out policies using Elisity's Simulation Mode to analyze impact on manufacturing processes, identify potential issues, and refine controls before enforcement, safeguarding your operations while protecting valuable research and production data.

Resources

Transform Your Pharma Network Security in Weeks, Not YearsElisity Microsegmentation: Accelerate Zero Trust Security in Weeks, Not Years

See how GSK reduced microsegmentation costs by 75% while protecting 275 global sites from ransomware and compliance violations. Discover Elisity's identity-based architecture—a leap forward that eliminates the need for new hardware, agents, VLANs, or complex ACLs.

Get the Details
Solution-Brief-card-reveal

Get Started

Stop East-West Attacks, Microsegment Your Networks

Learn why and how large enterprises are reducing risks and accelerating their Zero Trust maturity with Elisity. 
Learn More

Pharmaceutical Manufacturing & Biotech Security FAQ

See how Elisity helps pharmaceutical and biotech companies secure manufacturing systems while maintaining compliance and operational continuity. These FAQs answer the most common questions from security and manufacturing teams.

 

How does Elisity protect pharmaceutical manufacturing systems without requiring downtime?

Elisity's identity-based microsegmentation secures each system at the network level without requiring any software on validated equipment. By limiting communications to only what's necessary for manufacturing processes, it protects critical OT systems from threats.

Does Elisity help with FDA cybersecurity compliance and IEC 62443?

Yes, Elisity automatically discovers and classifies all connected manufacturing assets, then enforces zone-based segmentation policies that meet FDA OT guidance and IEC 62443 requirements. It provides the documentation and audit trails needed for regulatory compliance.

Can we implement this without impacting validated systems?

Absolutely. Elisity's agentless solution uses your existing network infrastructure, allowing you to deploy security policies without any changes to validated systems. You can simulate policies before enforcement to ensure no impact on GMP processes.

How does this simplify our pharmaceutical security operations?

Elisity consolidates OT security into one platform that understands manufacturing contexts. This unified approach means fewer consoles to manage and consistent enforcement across all sites, freeing your team from complex firewall and VLAN management.

Back to top

Resources

Zero Trust Assessment for Pharmaceutical and BioTech Companies: A Practical Implementation Guide
Zero Trust Assessment for Pharmaceutical and BioTech Companies: A Practical Implementation Guide

Zero Trust Assessment for Pharmaceutical and BioTech Companies: A Practical Implementation Guide

13 min read
FDA's New OT Cybersecurity Guidance: A Critical Roadmap for Pharmaceutical and Biotech Manufacturing Security
FDA's New OT Cybersecurity Guidance: A Critical Roadmap for Pharmaceutical and Biotech Manufacturing Security

FDA's New OT Cybersecurity Guidance: A Critical Roadmap for Pharmaceutical and Biotech Manufacturing Security

13 min read
List of Must-See Talks at Black Hat 2025 in Las Vegas
Black Hat 2025 List of Talks

List of Must-See Talks at Black Hat 2025 in Las Vegas

10 min read